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Poster Presentations: Sunday, July 14, 2019 P383discrimination. Visualization of learning process by guided Grad-
CAM revealed that CIS became more focused by the CNN as the
training progressed. DLB/AD score was significantly associated
with three core-features of DLB. Conclusions: Deep learning-based
imaging classification was useful not only for objective and accu-
rate differentiation of DLB from AD but also for predicting clinical
features of DLB. The CIS was identified as a specific feature during
DLB classification. The visualization of specific features and
learning process could have important implications for the potential
of deep learning to discover new imaging features.P1-349 ADVANCING CLINICAL AND BIOMARKER
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Contact e-mail: lapostol@iu.eduBackground: Approximately 5% of the 5.6 million (w280,000)
Americans with Alzheimer’s disease (AD) develop symptoms at age
65or younger and are classified as early-onsetAD(EOAD).Compared
to late-onset AD (LOAD), EOAD patients show lower prevalence of
amnestic versus non-amnestic presentations, more rapid cognitive
decline, more severe AD pathology and higher heritability. Sporadic
EOAD phenotypes are commonly excluded from observational
biomarker studies (e.g. ADNI) and therapeutic trials due to their age
and atypical presentation. Objective: The goals of the Longitudinal
Early-onset AD study (LEADS) are to 1) advance knowledge about
EOAD diagnosis, 2) develop sensitive clinical and biomarker tools
that capture EOAD progression, 3) establish EOAD site network for
interventional studies and 4) explore for novel genetic risk variants.
Poster Presentations: Sunday, July 14, 2019P384Methods: LEADSwill recruit and longitudinally followapproximately
400 amyloid-positive (EOAD), 100 amyloid-negative cognitively
impaired subjects (EOnonAD) and 100 age-matched controls. Partic-
ipants will undergo clinical and psychometric assessments, MRI, am-
yloid ([18F]Florbetaben) and tau ([18F]AV1451) PET, CSF, DNA,
RNA, plasma, serum and peripheral blood mononuclear cells collec-
tion at three time points. Methods are harmonized with ADNI and
DIAN to facilitate scientific comparisons.Results: LEADSenrollment
is ongoing. Demographics of the current sample are shown in Table.
Figure1 presents mean hippocampal volume as well as the mean ento-
rhinal and precuneal cortical thickness in the 17 CN, 12 EOAD and 6
EOnonAD with available MRI data. Group comparisons projected on
Freesusrfer-rendered 3D brain hemispheric models can be seen in
Figure 2. Figure 3 presents the mean global amyloid PET SUVR and
Figure 4 the mean tau PET deposition by early-, mid- and late-stage
Braak regions in 13 CN, 11 EOAD, 6 EOnonAD with both amyloidand tau PET data availability. The latest enrollment and study partici-
pant updates will be presented at the meeting. Conclusions: LEADS
will develop a publicly available natural history biomarker and clinical
data set in EOAD and will enable future planning and implementation
of clinical trials in EOAD. Successful completion of this project will
address several substantial gaps in our understanding of EOAD and
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Background: Cognitive reserve (CR) accounts for maintaining
functionality despite brain pathology. Recently, a residual
approach was introduced as a more specific measure of CR.
This approach considers the variance in cognition not being
explained by demographic and neuroimaging predictors as
CR measure. Here, we aimed to determine a functional
neuronal correlate of CR from resting-state functional MRI
(rs-fMRI). Methods: 103 cognitively normal subjects (mean
age 72.01 6 5.98) and 36 early amyloid-positive Alzheimer’s
disease (AD) patients (74.08 6 7.33) were included, for whom
neuropsychological data, an amyloid PET, and a rs-fMRI scan
were available at the Open Access Series of Imaging Studies
(OASIS; https://www.oasis-brains.org/). Information on global
amyloid load was assessed based on the Freesurfer-ROIs avail-
able in OASIS. Cognition residuals were computed regressing
global amyloid, ApoE status, age and sex onto cognitive test per-
formance using an exponential model fit. Positive residuals indi-
cate higher cognitive performance than predicted. Intrinsic
connectivity (IC) maps were extracted based on the pre-pro-
cessed rs-fMRI data using the CONN toolbox. Using general
linear modeling in SPM12 (p< .0001, uncor.), we first examined
the voxel-based association between the individual IC maps and
the cognition residuals in the early AD group, assuming this
group requires a high need for reserve. To determine if the iden-
tified neuronal CR correlate extends to the preclinical phase of
AD, we extracted the beta values of IC of the identified neuronal
CR correlate in the amyloid-positive cognitively normal group
(SUVR > 1.1, n¼57) and examined the relationship between
cognition residuals and IC. Results: Only increased IC in the
right hippocampus was associated with higher residuals in the
early AD group. In the amyloid-positive cognitively normal
group, the IC in this area was also correlated with greater resid-
uals (r¼.34, p<.05). The effect of the neuronal correlate and the
residuals was stronger in the AD group when comparing both
groups in terms of their correlation strengths. Conclusions: The
findings indicate that intrinsic hippocampal connectivity might
